Qian Qin, Wang Yu-Zhen, Kan Lian-Di, Chen Jie, Wang Chen, Han Gang, Li Liu-Cheng, Lou Wei-Jian
Department of Pharmacy, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, 310016, People's Republic of China.
Risk Manag Healthc Policy. 2023 Feb 27;16:287-299. doi: 10.2147/RMHP.S392224. eCollection 2023.
Pediatric hypertension become an early marker of cardiovascular diseases, but their antihypertensive drug use patterns are rarely known.
To investigate the epidemiological characteristics of pediatric hypertension and the use of antihypertensive drugs in the real world in China.
In this study, the demographic, diagnosis, and medication prescription data including the antihypertensive drug types and comorbidities, were analyzed. The antihypertensive drugs use were evaluated according to the Chinese guidelines for hypertension.
1301 prescriptions (number of visits) containing 1880 antihypertensive medical orders were collected. The average number of antihypertensive drugs per prescription was 1.45 (±0.75). The patients aged 16 to 18 (70.18%) accounted for the highest proportion. Kidney diseases (33.28%) were the most common comorbidities. Calcium channel blocker (CCB), angiotensin II receptor blocker (ARB), and β receptor blocker (BB) were the most used antihypertensive drugs. The most frequent monotherapy was CCB, while that of two and three drugs combination were ARB+CCB and ARB+BB+CCB, respectively. Metoprolol (11.44%), nifedipine (10.64%), amlodipine (10.59%), valsartan (6.12%) were the most commonly used antihypertensive drugs. The utilization rate of fixed compound preparations was 7.34%. However, the percentage of recommended antihypertensive drugs was just 14.20%, while the recommended drug combination was 84.93% according to the guidelines.
For the first time ever we reported the antihypertensive prescription analysis in children in a large area of China. Our data provided new insights into the epidemiological characteristics and drug use in hypertensive children. We found that the guidelines for medication management in hypertensive children were not routinely followed. The wide use of antihypertensive drugs in children and those with weak clinical evidence raised concerns regarding its rational use. The findings could lead to more effective management of hypertension in children.
儿童高血压成为心血管疾病的早期标志物,但其降压药物使用模式鲜为人知。
调查中国现实环境中儿童高血压的流行病学特征及降压药物的使用情况。
在本研究中,分析了人口统计学、诊断及药物处方数据,包括降压药物类型和合并症。根据中国高血压指南评估降压药物的使用情况。
收集到1301份包含1880条降压医嘱的处方(就诊次数)。每张处方的降压药物平均数量为1.45(±0.75)。16至18岁患者占比最高(70.18%)。肾脏疾病(33.28%)是最常见的合并症。钙通道阻滞剂(CCB)、血管紧张素II受体阻滞剂(ARB)和β受体阻滞剂(BB)是最常用的降压药物。最常见的单药治疗是CCB,而两药联合和三药联合分别是ARB+CCB和ARB+BB+CCB。美托洛尔(11.44%)、硝苯地平(10.64%)、氨氯地平(10.59%)、缬沙坦(6.12%)是最常用的降压药物。固定复方制剂的使用率为7.34%。然而,根据指南,推荐降压药物的比例仅为14.20%,而推荐药物联合的比例为84.93%。
我们首次报告了中国大面积儿童降压处方分析。我们的数据为高血压儿童的流行病学特征和药物使用提供了新见解。我们发现高血压儿童的药物管理指南未得到常规遵循。儿童中降压药物的广泛使用以及临床证据不足引发了对其合理使用的担忧。这些发现可能会使儿童高血压的管理更加有效。